Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Deals

Zhejiang Medicine’s NovoCodex Subsidiary Receives RMB 402M Investment

Fineline Cube Jul 6, 2022

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that investors will inject a financial dose...

Company Deals

Medicilon Biomedical Plans RMB 2.16B Private Placement for R&D Expansion

Fineline Cube Jul 6, 2022

China-based Shanghai Medicilon Biomedical Co., Ltd has announced plans to raise RMB 2.16 billion (USD...

Company Drug

Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA

Fineline Cube Jul 6, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...

Company Digital

Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss

Fineline Cube Jul 6, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...

Company Policy / Regulatory

Wuxi Biologics Set to Be Removed from US Restricted Trade List

Fineline Cube Jul 6, 2022

Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...

Policy / Regulatory R&D

CDE Releases 60th Batch of Chemical Generic Reference Preparations

Fineline Cube Jul 6, 2022

The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference...

Company Deals

Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies

Fineline Cube Jul 5, 2022

China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD...

Company Deals

Wuhan YZY Biopharma Raises RMB 200M for Bispecific Antibodies and COVID-19 Vaccine Development

Fineline Cube Jul 5, 2022

China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million)...

Company Deals

Shandong Xinhua Pharmaceutical Inks Tech Transfer Deal for LXH-2201 with IMM

Fineline Cube Jul 5, 2022

China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with...

Drug

Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China

Fineline Cube Jul 5, 2022

Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...

Company Drug

InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies

Fineline Cube Jul 5, 2022

Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the...

Company Drug

Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA –...

Company Deals

Techbank Medical Closes RMB 100M Series A to Build Global Innovation Platform

Fineline Cube Jul 5, 2022

Shanghai Techbank Medical Technology Co., Ltd, a cardiovascular device maker, has reportedly closed its Series...

Company Deals

PackGene and Genemagic Partner on AAV Production and CDMO Services

Fineline Cube Jul 5, 2022

China-based PackGene LLC has entered into a partnership with compatriot firm Genemagic Biosciences Co., Ltd....

Company Drug

PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...

Company Drug

Akeso Biopharma’s Cadonilimab Achieves National Delivery in China

Fineline Cube Jul 5, 2022

China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking...

Company Drug

Sobi’s Anakinra (Kineret) Prioritized for Review in China for FMF Treatment

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV:...

Company Drug

Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia

Fineline Cube Jul 5, 2022

China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III...

Policy / Regulatory

Guangdong Releases 2022 Non-Immunization Vaccine Catalog (7th Batch)

Fineline Cube Jul 5, 2022

The Guangdong Provincial Center for Disease Control and Prevention and Guangdong Medicine Exchange jointly released...

Company

WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing

Fineline Cube Jul 5, 2022

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...

Posts pagination

1 … 645 646 647 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.